Development and validation of a nomogram for predicting survival in intermediate- and high-risk neuroblastoma of the Children's Oncology Group risk stratification

被引:2
|
作者
Feng, Lijuan [1 ]
Kan, Ying [1 ]
Wang, Wei [1 ]
Wang, Chao [2 ]
Zhang, Hui [3 ]
Xie, Peng [4 ]
Yang, Jigang [1 ]
机构
[1] Capital Med Univ, Beijing Friendship Hosp, Dept Nucl Med, 95 Yong Rd, Beijing 100050, Peoples R China
[2] SinoUn Healthcare Inc, Beijing 100192, Peoples R China
[3] Tsinghua Univ, Sch Med, Dept Biomed Engn, Beijing 100084, Peoples R China
[4] Hebei Med Univ, Hosp 3, Dept Nucl Med, Shijiazhuang 050051, Peoples R China
关键词
Event-free survival; Neuroblastoma; Nomogram; Overall survival; Prognosis; MITOSIS-KARYORRHEXIS INDEX; CLASSIFICATION;
D O I
10.1007/s00432-023-05398-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeTo develop and validate a nomogram for predicting survival in intermediate- and high-risk neuroblastoma patients and to compare the accuracy of the nomogram in predicting survival with Children's Oncology Group (COG) risk stratification.MethodsA total of 885 intermediate- and high-risk neuroblastoma patients were enrolled in this study, including 243 patients from our hospital (the training set) and 642 patients from the TARGET database (the validation set). The factors related to event-free survival (EFS) and overall survival (OS) in neuroblastoma were determined to construct the nomogram by Cox regression analysis. The C-index, calibration curves, and area under the time-dependent receiver operating characteristic curves (AUCs) were used to assess the predictive performance of the nomogram.ResultsInternational Neuroblastoma Staging System stage and Mitosis-karyorrhexis index (MKI) were significant unfavorable factors for EFS, while MKI and MYCN status were significant unfavorable factors for OS. The C-index of the nomogram was 0.621 and 0.586 for predicting EFS, 0.650 and 0.570 for predicting OS in the training and validation sets, respectively. The calibration curves revealed good agreement in the EFS and OS predicted by the nomogram. The AUCs of the nomogram for 1-, 2-, 3-year EFS and OS were 0.633, 0.669, 0.604 and 0.672, 0.670, 0.702 in the training set, respectively. Moreover, the nomogram was able to classify patients into two groups according to risk scores, with the "high-risk" group having a lower survival rate than the "intermediate-risk" group. And the nomogram performed better than the COG risk stratification, which had a C-index of 0.537, 0.502 and 0.565, 0.572 for predicting EFS, OS in the training and validation sets, respectively.ConclusionWe developed and validated a prognostic nomogram for intermediate- and high-risk neuroblastoma patients that clinicians can use to make more informed decisions for individual patients.
引用
收藏
页码:16377 / 16390
页数:14
相关论文
共 50 条
  • [21] Pharmacogenetics of treatment response in patients with high-risk neuroblastoma: A Children's Oncology Group study.
    Pinto, Navin R.
    Emond, Mary J.
    Spiekerman, Charles
    Naranjo, Arlene
    Makar, Karen W.
    Park, Julie R.
    McCune, Jeannine S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [22] The role of age in neuroblastoma risk stratification: the German, Italian, and children's oncology group perspectives
    London, WB
    Boni, L
    Simon, T
    Berthold, F
    Twist, C
    Schmidt, ML
    Castleberry, RP
    Matthay, KK
    Cohn, SL
    De Bernardi, B
    CANCER LETTERS, 2005, 228 (1-2) : 257 - 266
  • [23] Racial and Ethnic Disparities in Risk and Survival in Children With Neuroblastoma: A Children's Oncology Group Study
    Henderson, Tara O.
    Bhatia, Smita
    Pinto, Navin
    London, Wendy B.
    McGrady, Patrick
    Crotty, Catherine
    Sun, Can-Lan
    Cohn, Susan L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (01) : 76 - 82
  • [24] Healthcare utilization disparities among children with high-risk neuroblastoma treated on Children's Oncology Group clinical trials
    Shoag, Jamie
    Li, Yimei
    Getz, Kelly D.
    Huang, Yuan-Shung
    Hall, Matt
    Naranjo, Arlene
    Richardson, Troy
    Desai, Ami V.
    Umaretiya, Puja J.
    Aziz-Bose, Rahela
    Kelly, Colleen A.
    Zheng, Daniel J.
    Newman, Haley
    Zahler, Stacey
    Aplenc, Richard
    Bagatell, Rochelle
    Bona, Kira
    PEDIATRIC BLOOD & CANCER, 2024, 71 (10)
  • [25] Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1
    Yanik, Gregory A.
    Parisi, Marguerite T.
    Naranjo, Arlene
    Nadel, Helen
    Gelfand, Michael J.
    Park, Julie R.
    Ladenstein, Ruth L.
    Poetschger, Ulrike
    Boubaker, Ariane
    Valteau-Couanet, Dominique
    Lambert, Bieke
    Castellani, Maria-Rita
    Bar-Sever, Zvi
    Oudoux, Aurore
    Kaminska, Anna
    Kreissman, Susan G.
    Shulkin, Barry L.
    Matthay, Katherine K.
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (03) : 502 - 508
  • [26] Stereotactic Body Radiation Therapy for Localized Prostate Cancer: Risk Stratification for Intermediate- and High-Risk Patients
    Katz, A.
    Kang, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E250 - E250
  • [27] Ototoxicity in Children With High-Risk Neuroblastoma: Prevalence, Risk Factors, and Concordance of Grading Scales-A Report From the Children's Oncology Group
    Landier, Wendy
    Knight, Kristin
    Wong, F. Lennie
    Lee, Jin
    Thomas, Ola
    Kim, Heeyoung
    Kreissman, Susan G.
    Schmidt, Mary Lou
    Chen, Lu
    London, Wendy B.
    Gurney, James G.
    Bhatia, Smita
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (06) : 527 - +
  • [28] Development and validation of a nomogram based on common biochemical indicators for survival prediction of children with high-risk neuroblastoma: A valuable tool for resource-limited hospitals
    Ruohao Wu
    Xiaohui Li
    Zhishan Chen
    Qiong Shao
    Xiao Zhang
    Wenting Tang
    Bo Hu
    BMC Pediatrics, 23
  • [29] Development and validation of a nomogram based on common biochemical indicators for survival prediction of children with high-risk neuroblastoma: A valuable tool for resource-limited hospitals
    Wu, Ruohao
    Li, Xiaohui
    Chen, Zhishan
    Shao, Qiong
    Zhang, Xiao
    Tang, Wenting
    Hu, Bo
    BMC PEDIATRICS, 2023, 23 (01)
  • [30] Localized intermediate- to high-risk prostate cancer
    Tritschler, S.
    Ganswindt, U.
    Stief, C. G.
    UROLOGE, 2016, 55 (03): : 318 - +